{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:18:47Z","timestamp":1783570727230,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11523-018-0582-1","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:58:09Z","timestamp":1533257889000},"page":"533-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Niraparib: A Review in Ovarian Cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"issue":"5","key":"582_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","volume":"209","author":"BK Erickson","year":"2013","unstructured":"Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409\u201314.","journal-title":"Am J Obstet Gynecol."},{"key":"582_CR2","doi-asserted-by":"publisher","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017; \n                    https:\/\/doi.org\/10.1038\/s41467-017-00962-1\n                    \n                  .","DOI":"10.1038\/s41467-017-00962-1"},{"key":"582_CR3","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (NCCN clinical practice guidelines in oncology). 2018. \n                    http:\/\/www.nccn.org\/\n                    \n                  . Accessed 10 May 2018."},{"issue":"1","key":"582_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"9951","key":"582_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376\u201388.","journal-title":"Lancet."},{"issue":"5","key":"582_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/CCO.0000000000000110","volume":"26","author":"S Khalique","year":"2014","unstructured":"Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014;26(5):521\u20138.","journal-title":"Curr Opin Oncol."},{"issue":"Suppl 1","key":"582_CR7","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","volume":"27","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i40\u2013i4.","journal-title":"Ann Oncol."},{"issue":"9","key":"582_CR8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882\u201392.","journal-title":"Lancet Oncol."},{"key":"582_CR9","unstructured":"TESARO Inc. Zejula\u00ae (niraparib): US prescribing information 2017. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 27 June 2018."},{"key":"582_CR10","unstructured":"European Medicines Agency. Zejula (niraparib) 100 mg hard capsules: summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 27 June 2018."},{"issue":"22","key":"582_CR11","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170\u201385.","journal-title":"J Med Chem."},{"issue":"2","key":"582_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2016.08.328","volume":"143","author":"MM AlHilli","year":"2016","unstructured":"AlHilli MM, Becker MA, Weroha SJ, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol. 2016;143(2):379\u201388.","journal-title":"Gynecol Oncol."},{"key":"582_CR13","unstructured":"European Medicines Agency. Zejula: European Public Assessment Report 2017. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 27 Dec 2017."},{"issue":"3","key":"582_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-017-3512-5","volume":"81","author":"K Moore","year":"2018","unstructured":"Moore K, Zhang ZY, Agarwal S, et al. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018;81(3):497\u2013503.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"8 Suppl 1","key":"582_CR15","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.clinthera.2017.05.025","volume":"39","author":"ZY Zhang","year":"2017","unstructured":"Zhang ZY, Kansra V, Van Andel L, et al. Characterization of absorption, metabolism, and elimination of niraparib, an investigational poly (adp-ribose) polymerase inhibitor, in cancer patients [abstract]. Clin Ther. 2017;39(8 Suppl 1):e7\u20138.","journal-title":"Clin Ther."},{"issue":"6","key":"582_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-017-0451-2","volume":"35","author":"L Andel van","year":"2017","unstructured":"van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investig New Drugs. 2017;35(6):751\u201365.","journal-title":"Investig New Drugs"},{"issue":"22","key":"582_CR17","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med."},{"issue":"15","key":"582_CR18","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res."},{"key":"582_CR19","doi-asserted-by":"publisher","unstructured":"Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018; \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy181\n                    \n                  .","DOI":"10.1093\/annonc\/mdy181"},{"issue":"15 Suppl 1","key":"582_CR20","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1200\/JCO.2017.35.15_suppl.5534","volume":"35","author":"UA Matulonis","year":"2017","unstructured":"Matulonis UA, Herrstedt J, Tinker A, et al. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC) [abstract no. 5534]. J Clin Oncol. 2017;35(15 Suppl 1):5534.","journal-title":"J Clin Oncol."},{"issue":"5 Suppl 5","key":"582_CR21","first-page":"2","volume":"15","author":"S Mahner","year":"2017","unstructured":"Mahner S, Mirza MR, Moore K, et al. ENGOT-OV16\/NOVA: results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer. Clin Adv Hematol Oncol. 2017;15(5 Suppl 5):2\u20133.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"Suppl 5","key":"582_CR22","first-page":"v330","volume":"28","author":"M Fabbro","year":"2017","unstructured":"Fabbro M, Moore K, D\u00f8rum A, et al. Safety and efficacy of niraparib in elderly patients (pts) with recurrent ovarian cancer (OC) [abstract no. 934PD]. Ann Oncol. 2017;28(Suppl 5):v330\u2013v54.","journal-title":"Ann Oncol."},{"issue":"Suppl 6","key":"582_CR23","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","journal-title":"Ann Oncol."},{"key":"582_CR24","unstructured":"Ledermann J, Sessa C, Colombo N on behalf of the ESMO guidelines committee. eUpdate \u2013 ovarian cancer treatment recommendations 2016. \n                    http:\/\/www.esmo.org\n                    \n                  . Accessed 19 Mar 2018."},{"key":"582_CR25","unstructured":"National Institue for Health and Care Excellence. Final appraisal determination: niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. 2018. \n                    http:\/\/www.nice.org.uk\n                    \n                  . Accessed 5 June 2018."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0582-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0582-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0582-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T23:12:14Z","timestamp":1564787534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0582-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0582-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"3 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo and Sean Duggan are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}